Skip to main content
Top
Published in: Journal of Cardiothoracic Surgery 1/2018

Open Access 01-12-2018 | Case report

R0 resection and reconstruction for a large, rapidly progressive chest wall sarcoma

Authors: Robert L. Kress, Shraddha M. Dalwadi, Adel D. Irani

Published in: Journal of Cardiothoracic Surgery | Issue 1/2018

Login to get access

Abstract

Background

Chest wall sarcomas are a rare group of soft tissue malignancies with variable presentations. Here we describe the definitive management of a large, rapidly progressing chest wall sarcoma arising from the pectoralis major muscle.

Case report

An obese 42-year-old African American male with multiple medical comorbidities presented with new onset right-sided chest pain and a palpable right chest mass. Initial CT chest demonstrated a 9x9x9cm necrotic mass arising from the pectoralis major. CT-guided core biopsy was positive for high-grade spindle cell neoplasm (positive for smooth muscle actin, desmin, S100, and CD31; negative for CD34, PAX8, and beta-catenin). Staging imaging 2 months later demonstrated growth of the mass to 21.4 × 17.8 × 13.7 cm. The patient underwent neoadjuvant chemoradiation with surveillance CT imaging demonstrating a stable tumor. Then he underwent wide local excision of the mass followed by delayed local myocutaneous flap reconstruction and skin grafting. Final pathology was R0 resection, 38x20x18 cm tumor with 70% gross necrosis. Microscopic examination confirmed high-grade sarcoma with smooth muscle differentiation. Final pathologic staging was Stage III G3 pT2bNxMx.

Conclusions

This patient presented with a rare, rapidly enlarging high-grade leiomyosarcoma of the chest wall without metastases or violation of the thorax. We describe the definitive management including a multidisciplinary team to manage a complex and rapidly progressive sarcoma of the chest wall.
Literature
2.
go back to reference Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23–47.CrossRef Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23–47.CrossRef
3.
go back to reference Gross JL, et al. Soft-tissue sarcomas of the chest wall: prognostic factors. Chest. 2005;127:902–8.CrossRef Gross JL, et al. Soft-tissue sarcomas of the chest wall: prognostic factors. Chest. 2005;127:902–8.CrossRef
4.
go back to reference McMillan RR, Sima CS, Moraco NH, Rusch VW, Huang J. Recurrence patterns after resection of soft tissue sarcomas of the chest wall. Ann Thorac Surg. 2013;96:1223–8.CrossRef McMillan RR, Sima CS, Moraco NH, Rusch VW, Huang J. Recurrence patterns after resection of soft tissue sarcomas of the chest wall. Ann Thorac Surg. 2013;96:1223–8.CrossRef
5.
go back to reference Wouters MW, et al. Outcome after surgical resections of recurrent chest wall sarcomas. J Clin Oncol. 2008;26:5113–8.CrossRef Wouters MW, et al. Outcome after surgical resections of recurrent chest wall sarcomas. J Clin Oncol. 2008;26:5113–8.CrossRef
6.
go back to reference Kucharczuk, J. C. Chest wall sarcomas and induction therapy. Thorac Surg Clin 22, 77–81, vii (2012). Kucharczuk, J. C. Chest wall sarcomas and induction therapy. Thorac Surg Clin 22, 77–81, vii (2012).
7.
go back to reference Gronchi A, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017;18:812–22.CrossRef Gronchi A, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017;18:812–22.CrossRef
8.
go back to reference Seddon B, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1397–410.CrossRef Seddon B, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1397–410.CrossRef
9.
go back to reference Tsukushi S, Nishida Y, Sugiura H, Nakashima H, Ishiguro N. Soft tissue sarcomas of the chest wall. J Thorac Oncol. 2009;4:834–7.CrossRef Tsukushi S, Nishida Y, Sugiura H, Nakashima H, Ishiguro N. Soft tissue sarcomas of the chest wall. J Thorac Oncol. 2009;4:834–7.CrossRef
10.
go back to reference van Geel AN, Wouters MWJM, Lans TE, Schmitz PIM, Verhoef C. Chest wall resection for adult soft tissue sarcomas and chondrosarcomas: analysis of prognostic factors. World J Surg. 2011;35:63–9.CrossRef van Geel AN, Wouters MWJM, Lans TE, Schmitz PIM, Verhoef C. Chest wall resection for adult soft tissue sarcomas and chondrosarcomas: analysis of prognostic factors. World J Surg. 2011;35:63–9.CrossRef
11.
go back to reference Friesenbichler J, et al. Surgical therapy of primary malignant bone tumours and soft tissue sarcomas of the chest wall: a two-institutional experience. Int Orthop. 2014;38:1235–40.CrossRef Friesenbichler J, et al. Surgical therapy of primary malignant bone tumours and soft tissue sarcomas of the chest wall: a two-institutional experience. Int Orthop. 2014;38:1235–40.CrossRef
12.
go back to reference Sabbagh C, Maggiori L, Panis Y. Management of failed low colorectal and coloanal anastomosis. J Visc Surg. 2013;150:181–7.CrossRef Sabbagh C, Maggiori L, Panis Y. Management of failed low colorectal and coloanal anastomosis. J Visc Surg. 2013;150:181–7.CrossRef
13.
go back to reference Gordon MS, Hajdu SI, Bains MS, Burt ME. Soft tissue sarcomas of the chest wall results of surgical resection. J Thorac Cardiovasc Surg. 1991;101:843–54.PubMed Gordon MS, Hajdu SI, Bains MS, Burt ME. Soft tissue sarcomas of the chest wall results of surgical resection. J Thorac Cardiovasc Surg. 1991;101:843–54.PubMed
14.
go back to reference Burt A, et al. Treatment of chest wall sarcomas: a single-institution experience over 20 years. Am J Clin Oncol. 2015;38:80–6.CrossRef Burt A, et al. Treatment of chest wall sarcomas: a single-institution experience over 20 years. Am J Clin Oncol. 2015;38:80–6.CrossRef
15.
go back to reference Nishiyama Y, et al. Prediction of treatment outcomes in patients with chest wall sarcoma: evaluation with PET/CT. Jpn J Clin Oncol. 2012;42:912–8.CrossRef Nishiyama Y, et al. Prediction of treatment outcomes in patients with chest wall sarcoma: evaluation with PET/CT. Jpn J Clin Oncol. 2012;42:912–8.CrossRef
16.
go back to reference Putnam JB Jr. Outcomes of surgery for chest wall sarcomas. Thorac Surg Clin. 2010;20:535–42.CrossRef Putnam JB Jr. Outcomes of surgery for chest wall sarcomas. Thorac Surg Clin. 2010;20:535–42.CrossRef
Metadata
Title
R0 resection and reconstruction for a large, rapidly progressive chest wall sarcoma
Authors
Robert L. Kress
Shraddha M. Dalwadi
Adel D. Irani
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Journal of Cardiothoracic Surgery / Issue 1/2018
Electronic ISSN: 1749-8090
DOI
https://doi.org/10.1186/s13019-018-0812-8

Other articles of this Issue 1/2018

Journal of Cardiothoracic Surgery 1/2018 Go to the issue